未登录 分享 收藏
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study von Pawel, J.; Bordoni, R.; Satouchi, M.; Fehrenbacher, L.; Cobo, M.; Han, J. Y.; Hida, T.; Moro-Sibilot, D.; Conkling, P.; Gandara, D. R.; Rittmeyer, A.; Gandhi, M.; Yu, W.; Matheny, C.; Patel, H.; Sandler, A.; Ballinger, M.; Kowanetz, M.; Park, K. 分享 收藏
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer Bordoni, Rodolfo; Ciardiello, Fortunato; von Pawel, Joachim; Cortinovis, Diego; Karagiannis, Thomas; Ballinger, Marcus; Sandier, Alan; Yu, Wei; He, Pei; Matheny, Christina; Felizzi, Federico; Rittmeyer, Achim 分享 收藏
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial Christopoulos, P.; Engel-Riedel, W.; Grohe, C.; Kropf-Sanchen, C.; von Pawel, J.; Guetz, S.; Kollmeier, J.; Eberhardt, W.; Ukena, D.; Baum, V.; Nimmrich, I.; Sieder, C.; Schnabel, P. A.; Serke, M.; Thomas, M. 分享 收藏
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study Gottfried, Maya; Bennouna, Jaafar; Bondarenko, Igor; Douillard, Jean-Yves; Heigener, David F.; Krzakowski, Maciej; Mellemgaard, Anders; Novello, Silvia; Orlov, Sergei; Summers, Yvonne; von Pawel, Joachim; Stoehr, Julia; Kaiser, Rolf; Reck, Martin 分享 收藏
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial 阿特珠单抗与多西他赛在先前治疗的非小细胞肺癌 (OAK) 患者中的比较: 一项3期，开放标签，多中心随机对照试验 Rittmeyer, Achim; Barlesi, Fabrice; Waterkamp, Daniel; Park, Keunchil; Ciardiello, Fortunato; von Pawel, Joachim; Gadgeel, Shirish M.; Hida, Toyoaki; Kowalski, Dariusz M.; Dols, Manuel Cobo; Cortinovis, Diego L.; Leach, Joseph; Polikoff, Jonathan; Barrios, Carlos; Kabbinavar, Fairooz; Frontera, Osvaldo Aren; De Marinis, Filippo; Turna, Hande; Lee, Jong-Seok; Ballinger, Marcus; Kowanetz, Marcin; He, Pei; Chen, Daniel S.; Sandler, Alan; Gandara, David R. 分享 收藏
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC Barlesi, F.; Park, K.; Ciardiello, F.; von Pawel, J.; Gadgeel, S.; Hida, T.; Kowalski, D.; Dols, M. C.; Cortinovis, D.; Leach, J.; Polikoff, J.; Gandara, D.; Barrios, C. H.; Chen, D. S.; He, P.; Kowanetz, M.; Ballinger, M.; Waterkamp, D.; Sandler, A.; Rittmeyer, A. 分享 收藏
Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study Heigener, D.; Gottfried, M.; Bennouna, J.; Bondarenko, I.; Douillard, J-Y.; Krzakowski, M.; Mellemgaard, A.; Novello, S.; Orlov, S.; Summers, Y. J.; von Pawel, J.; Hocke, J.; Kaiser, R.; Reck, M. 分享 收藏
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)aEuro Joerger, M.; von Pawel, J.; Kraff, S.; Fischer, J. R.; Eberhardt, W.; Gauler, T. C.; Mueller, L.; Reinmuth, N.; Reck, M.; Kimmich, M.; Mayer, F.; Kopp, H. -G.; Behringer, D. M.; Ko, Y. -D.; Hilger, R. A.; Roessler, M.; Kloft, C.; Henrich, A.; Moritz, B.; Miller, M. C.; Salamone, S. J.; Jaehde, U. 分享 收藏
Amisulpride, a dopamine D2/D3-antagonist, prevents chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic cisplatin or anthracycline-cyclophosphamide regimens: A randomised, double-blind, placebo-controlled, dose-ranging trial Herrstedt, J.; Summers, Y.; Jordan, K.; Von Pawel, J.; Jakobsen, A. H.; Ewertz, M.; Chan, S.; Naik, J.; Karthaus, M.; Dubey, S.; Davis, R.; Fox, G. 分享 收藏
Pharmacokinetically (PK)-guided dosing of paclitaxel in combination with carboplatin in advanced non-small cell lung cancer (NSCLC) is gender dependent: Updated results of the randomized CEPAC-TDM study Joerger, M.; Von Pawel, J.; Kraff, S.; Fischer, J. R.; Gauler, T.; Mueller, L.; Reinmuth, N.; Reck, M.; Kimmich, M.; Frank, M.; Kopp, H. G.; Behringer, D.; Ko, Y. D.; Ralf, H.; Roessler, M.; Kloft, C.; Henrich, A.; Moritz, B.; Jaehde, U. 分享 收藏
分享 收藏
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EVOFOSFAMIDE (TH-302) IN COMBINATION WITH PEMETREXED IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER Goldman, J.; Belani, C.; Novello, S.; von Pawel, J.; Csoszi, T.; Orlov, S.; Kroll, S.; Pearce, T. 分享 收藏
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer Mendell, Jeanne; Freeman, Daniel J.; Feng, Wenqin; Hettmann, Thore; Schneider, Matthias; Blum, Sabine; Ruhe, Jens; Bange, Johannes; Nakamaru, Kenji; Chen, Shuquan; Tsuchihashi, Zenta; von Pawel, Joachim; Copigneaux, Catherine; Beckmana, Robert A. 分享 收藏
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer Novello, Silvia; Kaiser, Rolf; Mellemgaard, Anders; Douillard, Jean-Yves; Orlov, Sergey; Krzakowski, Maciej; von Pawel, Joachim; Gottfried, Maya; Bondarenko, Igor; Liao, Meilin; Barrueco, Jose; Gaschler-Markefski, Birgit; Griebsch, Ingolf; Palmer, Michael; Reck, Martin 分享 收藏
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer Chiappori, A. A.; Kolevska, T.; Spigel, D. R.; Hager, S.; Rarick, M.; Gadgeel, S.; Blais, N.; Von Pawel, J.; Hart, L.; Reck, M.; Bassett, E.; Burington, B.; Schiller, J. H. 分享 收藏
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer Novello, S.; Besse, B.; Felip, E.; Barlesi, F.; Mazieres, J.; Zalcman, G.; von Pawel, J.; Reck, M.; Cappuzzo, F.; Ferry, D.; Carcereny, E.; Santoro, A.; Garcia-Ribas, I.; Scagliotti, G.; Soria, J. -C. 分享 收藏
A randomized, open-label phase 2 study of efatutazone and erlotinib as second- or third-line therapy for non-small cell lung cancer (NSCLC) Oton, Ana B.; Cho, Byoung Chul; Ahn, Myung-Ju; Kim, Sang-We; Subramanian, Kirushnakumar; Desai, Chirag; Shuster, Dale; Goldberg, Terri; Zahir, Hamim; Dutta, Dipen; Chen, Shuquan; Von Roemeling, Richard; von Pawel, Joachim 分享 收藏
A randomised phase II study of pemetrexed versus pemetrexed plus erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer 培美曲塞与培美曲塞联合厄洛替尼二线治疗局部晚期或转移性非鳞状非小细胞肺癌的随机II期研究 Dittrich, Christian; Papai-Szekely, Zsolt; Vinolas, Nuria; Sederholm, Christer; Hartmann, Joerg T.; Behringer, Dirk; Kazeem, Gbenga; Desaiah, Durisala; Leschinger, Monika I.; von Pawel, Joachim 分享 收藏
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer von Pawel, Joachim; Harvey, Jimmie H.; Spigel, David R.; Dediu, Mircea; Reck, Martin; Cebotaru, Cristina L.; Humphreys, Robin C.; Gribbin, Matthew J.; Fox, Norma Lynn; Camidge, D. Ross 分享 收藏
.png){kind=icon}
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}